文献速递乳腺癌

内分泌治疗对比化疗用于绝经后HR阳性HER2阴性转移性乳腺癌:系统综述与网络Meta分析

Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis.
PubMed 文献 · Lancet Oncol · 2019-09-04

该网络Meta分析纳入140项随机对照试验共50 029例绝经后HR阳性HER2阴性转移性乳腺癌患者,比较一线或二线内分泌治疗与化疗。结果显示CDK4/6抑制剂联合内分泌治疗的无进展生存优于单药阿那曲唑,且无化疗方案显著优于帕博西利联合来曲唑。

要点

  • CDK4/6抑制剂联合内分泌治疗较单药阿那曲唑显著改善PFS。
  • 无化疗方案(含或不含靶向)在PFS上显著优于帕博西利联合来曲唑。
  • 帕紫醇联合贝伐珠单抗是唯一在客观缓解率上显著优于帕博西利联合来曲唑的方案。

核心结论

  • 一线或二线治疗中,CDK4/6抑制剂联合内分泌治疗在PFS上优于标准内分泌治疗。
  • 无化疗方案(含或不含靶向)在PFS上未显著优于CDK4/6抑制剂联合内分泌治疗。

研究设计与样本

  • 系统综述与贝叶斯网络Meta分析,检索PubMed、Embase、Cochrane、Web of Science及会议档案。
  • 共纳入140项研究、50 029例绝经后HR阳性HER2阴性转移性乳腺癌患者。

临床怎么用

  • 支持指南推荐将内分泌治疗联合靶向治疗作为HR阳性HER2阴性转移性乳腺癌的一线或二线治疗。
  • CDK4/6抑制剂联合内分泌治疗可作为优先考虑的方案,而非化疗。

局限性

  • 未报告资助信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although international guidelines support the administration of hormone therapies with or without targeted therapies in postmenopausal women with hormone-receptor-positive, HER2-negative metastatic breast cancer, upfront use of chemotherapy remains common even in the absence of visceral crisis. Because first-line or second-line treatments, or both, based on chemotherapy and on hormone therapy have been scarcely investigated in head-to-head randomised controlled trials, we aimed to compare these two different approaches. METHODS: We did a systematic review and network meta-analysis with a systematic literature search on PubMed, Embase, Cochrane Central Register of Clinical Trials, Web of Science, and online archives of the most relevant international oncology conferences. We included all phase 2 and 3 randomised controlled trials investigating chemotherapy with or without targeted therapies and hormone therapies with or without targeted therapies as first-line or second-line treatments, or both, in postmenopausal women with hormone-receptor-positive, HER2-negative metastatic breast cancer, published between Jan 1, 2000, and Dec 31, 2017. Additional recently published randomised controlled trials relevant to the topic were also subsequently added. No language restrictions were adopted for our search. A Bayesian network meta-analysis was done to compare hazard ratios (HRs) for progression-free survival (the primary outcome), and to compare odds ratios (ORs) for the proportion of patients achieving an overall response (the secondary outcome). All treatments were compared to anastrozole and to palbociclib plus letrozole. This study is registered in the Open Science Framework online public database, registration DOI 10.17605/OSF.IO/496VR. FINDINGS: We identified 2689 published results and 140 studies (comprising 50 029 patients) were included in the analysis. Palbociclib plus letrozole (HR 0·42; 95% credible interval [CrI] 0·25-0·70), ribociclib plus letrozole (0·43; 0·24-0·77), abemaciclib plus anastrozole or letrozole (0·42; 0·23-0·76), palbociclib plus fulvestrant (0·37; 0·23-0·59), ribociclib plus fulvestrant (0·48; 0·31-0·74), abemaciclib plus fulvestrant (0·44; 0·28-0·70), everolimus plus exemestane (0·42; 0·28-0·67), and, in patients with a PIK3CA mutation, alpelisib plus fulvestrant (0·39; 0·22-0·66), and several chemotherapy-based regimens, including anthracycline and taxane-containing regimens, were associated with better progression-free survival than was anastrozole alone. No chemotherapy or hormone therapy regimen was significantly better than palbociclib plus letrozole for progression-free survival. Paclitaxel plus bevacizumab was the only clinically relevant regimen that was significantly better than palbociclib plus letrozole in terms of the proportion of patients achieving an overall response (OR 8·95; 95% CrI 1·03-76·92). INTERPRETATION: In the first-line or second-line setting, CDK4/6 inhibitors plus hormone therapies are better than standard hormone therapies in terms of progression-free survival. Moreover, no chemotherapy regimen with or without targeted therapy is significantly better than CDK4/6 inhibitors plus hormone therapies in terms of progression-free survival. Our data support treatment guideline recommendations involving the new combinations of hormone therapies plus targeted therapies as first-line or second-line treatments, or in both settings, in women with hormone-receptor-positive, HER2-negative metastatic breast cancer. FUNDING: None.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Giuliano M, Schettini F, Rognoni C, et al. Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis. Lancet Oncol. 2019. PMID: 31494037. doi:10.1016/S1470-2045(19)30420-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。